Scoop: CNS biotech Map­Light Ther­a­peu­tics eyes $175M raise for PhII clin­i­cal tri­als in schiz­o­phre­nia, autism and Parkin­son's

Map­Light Ther­a­peu­tics, a biotech fo­cused on cen­tral ner­vous sys­tem dis­or­ders, is eye­ing a large $175 mil­lion fi­nanc­ing as it beefs up the C-suite and ad­vances mul­ti­ple drug can­di­dates. The biotech has so far raised $50 mil­lion from five in­vestors in the of­fer­ing, per a Wednes­day SEC fil­ing.

The start­up has said lit­tle about its in­vestors to-date. Nan Fung Group’s Piv­otal Life Sci­ences start­ed back­ing the biotech around its in­cep­tion in 2019, and the Michael J. Fox Foun­da­tion has pro­vid­ed mul­ti­ple grants. Map­Light had raised $63 mil­lion in fund­ing as of last No­vem­ber and had 49 em­ploy­ees as of last month, ac­cord­ing to da­ta from Pitch­Book.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER